Browsing by Author "Momblan, Dulce"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Endoscopic full-thickness resection of esophagogastric junction gastrointestinal stromal tumor assisted by laparoscopy after neoadjuvant therapy(Georg Thieme Verlag KG Stuttgart · New York, 2016) Navarrete, Andrés; Momblan, Dulce; Fernández, Gloria; Delgado, Salvadora; Jiménez, Marta; Hessheimer, Amelia; Lacy, AntonioGastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the digestive tract [1]. Surgery is the only potentially curative therapy. However, some tumors are locally advanced, and therefore R0 resection cannot be guaranteed. In this situation, imatinib can allow organ-preserving surgery and optimal oncological outcome GISTs located at the esophagogastric junction (EGJ) are challenging because wedge resection is difficult to achieve, and gastrectomy and/or esophagectomy are associated with morbidity and mortality. Consequently, endoscopic resection could be an ideal alternative to surgery, with comparable oncological outcomes. We present the case of an 82-year-old woman with a 1-month history of progressive dysphagia. An upper endoscopy showed a 6-cm pedunculated polypoid lesion at the EGJ, with a short and wide pedicle that protruded into the gastric fundus. The biopsy demonstrated a high-risk GIST with 20 mitoses per 50 high-power fields (HPF). Abdominal double-contrast radiography and computed tomography (CT) scan ruled out metastasis. It was decided to treat the tumor with imatinib to decrease its size. A 6-month course of therapy was started.Item Giant Gastric Gastrointestinal Stromal Tumor (GIST)(Springer, 2016) Navarrete, Andres; Momblan, Dulce; Almenara, Raul; Lacy, AntonioGastrointestinal stromal tumors (GIST) represent 0.1–3 % of gastrointestinal malignancy. Surgery is the mainstay of treatment, but in high-risk tumors, imatinib can help to achieve better oncological outcomes. We present a rare case of a patient with gastric GIST with very aggressive evolution in a short period of time despite the use of neoadjuvant therapy with imatinib.